Alvotech and teva announce u.s. approval of simlandi® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to humira®

Alvotech (nasdaq: alvo) and teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced that the u.s. food and drug administration (fda) has approved simlandi (adalimumab-ryvk) injection, as an interchangeable biosimilar to humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul
ALVO Ratings Summary
ALVO Quant Ranking